Skip to content

News releases

The following are news releases and statements issued by Biosimilars Canada. News stories about biosimilars that may be of interest to readers are available here.

Advisory Council on the Implementation of National Pharmacare Highlights Importance of Biosimilar Medicines

The Advisory Council on the Implementation of National Pharmacare’s Final Report highlights the importance of biosimilar medicines in the sustainable implementation of a national pharmacare program.
Read more

BC PharmaCare Expands Use of Biosimilar Medicines
First Province to Implement Large-Scale Biologic Switching Program

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of British Columbia for announcing a program in which patients taking originator biologic drugs will be “switched” or transitioned by their clinicians to a biosimilar biologic drug within a six-month period.
Read more

Biosimilars Canada Announces Patient Support Program Platform

Biosimilars Canada, the national association representing Canada’s biosimilar medicines industry, today announced that Innomar Strategies, Canada's leading specialty pharmaceuticals service provider has been selected as the preferred provider for the Biosimilars Canada Patient Support Program (PSP) platform.
Read more

European Experience and Evidence of Physician-led Switching of Biological Medicines Give Hope to Patients around the World

Read more
Read more

Biosimilars Canada Statement on Revised Canadian Guidance for Sponsors of Biosimilars

The convergence of regulatory requirements is a top priority for sponsors of biosimilar medicines as single global development programs are typical given the high R&D costs for these complex products.
Read more

IGBA call for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposal

Read more
Read more